BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 26389665)

  • 1. Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.
    Li Y; Zhou QL; Sun W; Chandrasekharan P; Cheng HS; Ying Z; Lakshmanan M; Raju A; Tenen DG; Cheng SY; Chuang KH; Li J; Prabhakar S; Li M; Tergaonkar V
    Nat Cell Biol; 2015 Oct; 17(10):1327-38. PubMed ID: 26389665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1.
    Xu X; Li Y; Bharath SR; Ozturk MB; Bowler MW; Loo BZL; Tergaonkar V; Song H
    Nat Commun; 2018 Aug; 9(1):3183. PubMed ID: 30093619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NFκB drives TERT promoter reactivation in cancer.
    Tergaonkar V
    Cell Cycle; 2016; 15(2):156-7. PubMed ID: 26588470
    [No Abstract]   [Full Text] [Related]  

  • 4. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
    Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
    Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression.
    Sim N; Li Y
    Commun Biol; 2023 Apr; 6(1):445. PubMed ID: 37087499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation of telomerase in cancer.
    Akincilar SC; Unal B; Tergaonkar V
    Cell Mol Life Sci; 2016 Apr; 73(8):1659-70. PubMed ID: 26846696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ets2 transcription factor, telomerase activity and breast cancer.
    Dwyer JM; Liu JP
    Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):83-7. PubMed ID: 19566835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.
    de Oliveira KA; Kaergel E; Heinig M; Fontaine JF; Patone G; Muro EM; Mathas S; Hummel M; Andrade-Navarro MA; Hübner N; Scheidereit C
    Genome Med; 2016 Mar; 8(1):28. PubMed ID: 26988706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF
    Gabler L; Lötsch D; Kirchhofer D; van Schoonhoven S; Schmidt HM; Mayr L; Pirker C; Neumayer K; Dinhof C; Kastler L; Azizi AA; Dorfer C; Czech T; Haberler C; Peyrl A; Kumar R; Slavc I; Spiegl-Kreinecker S; Gojo J; Berger W
    Acta Neuropathol Commun; 2019 Aug; 7(1):128. PubMed ID: 31391125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.
    Ahmad F; Dixit D; Sharma V; Kumar A; Joshi SD; Sarkar C; Sen E
    Cell Death Dis; 2016 May; 7(5):e2213. PubMed ID: 27148686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
    Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
    Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of the Notch effector RBPJ promotes tumorigenesis.
    Kulic I; Robertson G; Chang L; Baker JH; Lockwood WW; Mok W; Fuller M; Fournier M; Wong N; Chou V; Robinson MD; Chun HJ; Gilks B; Kempkes B; Thomson TA; Hirst M; Minchinton AI; Lam WL; Jones S; Marra M; Karsan A
    J Exp Med; 2015 Jan; 212(1):37-52. PubMed ID: 25512468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase directly regulates NF-κB-dependent transcription.
    Ghosh A; Saginc G; Leow SC; Khattar E; Shin EM; Yan TD; Wong M; Zhang Z; Li G; Sung WK; Zhou J; Chng WJ; Li S; Liu E; Tergaonkar V
    Nat Cell Biol; 2012 Dec; 14(12):1270-81. PubMed ID: 23159929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Single Nucleotide Polymorphism Increases TERT Promoter Activity in Thyroid Carcinoma Cells.
    Hirokawa T; Arimasu Y; Chiba T; Nakazato Y; Fujiwara M; Kamma H
    Pathobiology; 2020; 87(6):338-344. PubMed ID: 33227798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEBP factors regulate telomerase reverse transcriptase promoter activity in whey acidic protein-T mice during mammary carcinogenesis.
    Kumar M; Witt B; Knippschild U; Koch S; Meena JK; Heinlein C; Weise JM; Krepulat F; Kuchenbauer F; Iben S; Rudolph KL; Deppert W; Günes C
    Int J Cancer; 2013 May; 132(9):2032-43. PubMed ID: 23023397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
    Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
    Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
    Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
    Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutation in adult granulosa cell tumor of the ovary.
    Pilsworth JA; Cochrane DR; Xia Z; Aubert G; Färkkilä AEM; Horlings HM; Yanagida S; Yang W; Lim JLP; Wang YK; Bashashati A; Keul J; Wong A; Norris K; Brucker SY; Taran FA; Krämer B; Staebler A; van Meurs H; Oliva E; Shah SP; Kommoss S; Kommoss F; Gilks CB; Baird DM; Huntsman DG
    Mod Pathol; 2018 Jul; 31(7):1107-1115. PubMed ID: 29449679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.